

Dr. Chiara Zecca, Publication list

Original works in Peer Reviewed-Journals as first or last author

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
18	Zecca C , Pavelek Z, Prikrylova K, Ghielmetti M, Beeler A, Gobbi C. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: the SFERA Study. Multiple Sclerosis and related Disorders 2019 May 2019;30C:104-109. doi.org/10.1016/j.msard.2019.02.010	3.199	
17	Zecca C , Bellavia G, Brambilla L, Gutierrez LP, Gerardi C, Fiori AM, Bernardini LR, Camera G, Disanto G, Petrini L, Perugini J, Antozzi CG, Torri Clerici V, Bellino A, Confalonieri PA, Gobbi C, Mantegazza RE, Rossi S. Atypical post-injection reactions with delayed onset following glatiramer acetate 40 mg: need of titration? CNS Drugs 2018; 32(7):653-660; https://doi.org/10.1007/s40263-018-0529-1	4.206	38/197 (Clinical Neurology) 37/260 (Pharmacology & Pharmacy) 29/202 (Psychiatry)
16	Scotti B, Disanto G, Sacco R, Guigli M, Zecca C* , Gobbi C* (*equal contribution) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 2018; 13(5): e0197415. https://doi.org/10.1371/journal.pone.0197415	2.766	15/64 (Multidisciplinary Sciences)
15	Zecca C , Roth S, Findling O, Perriard G, Bachmann V, Pless M, Baumann A, Kamm C, Lalive P, Czaplinski A. Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). Eur J Neurol. 2018 May;25(5):762-767. doi: 10.1111/ene.13594. Epub 2018 Mar 6.	3.988	41/194 (Clinical Neurology) 66/259 (Neurosciences)
14	Zecca C , Disanto G, Mühl S, Gobbi C. Subjective patient-reported versus objective adherence to subcutaneous interferon β -1a in multiple sclerosis using RebiSmart®: the CORE study. BMC Neurol. 2017 Sep 4;17(1):171. doi: 10.1186/s12883-017-0952-9. http://rdcu.be/vz7x .	2.006	Q2 Clinical Neurology
13	Zecca C , Merlini A, Disanto G, Rodegher M, Panicari L, Romeo M, Candrian U, Josè Messina M, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V. Half-dose fingolimod for treating relapsing remitting multiple sclerosis - Observational study. Mult Scler 2018;24(2):167-174.; DOI: 10.1177/ 1352458517694089, First Published February 1, 2017.	4.671	27/193 (Clinical Neurology)
12	Pravatà E*, Zecca C* , Sestieri C, Caulo M, Riccitelli GC, Rocca MA, Filippi M, Cianfoni A, Gobbi C (*equal contribution). Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue. Mult Scler 2016; 22(13): 1665-1675. doi: 10.1177/1352458515625806.	4.822	22/192 (Clinical Neurology)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
11	Zecca C , Riccitelli G, Disanto G, Singh A, Digesu A, Panicari L, Puccini F, Mattioli M, Tubaro A, Gobbi C. Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life. Eur J Neurol 2016; 23: 1228-1234. doi: 10.1111/ene.13010.	4.055	28/192 (Clinical Neurology)
10	Zecca C , Disanto G, Sormani MP, Riccitelli GC, Cianfoni A, Delgrande F, Pravatà E, Gobbi C. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler. 2016 May;22(6):782-91. doi: 10.1177/1352458515599246.	4.822	22/192 (Clinical Neurology)
09	Zecca C , Heldner MR, Kamm CP, Riccitelli GC, Disanto G, Caporro M, Cianfoni A, Pravatà E, Gobbi C. Natalizumab in spinal multiple sclerosis in a daily clinical setting. Expert Opinion On Biological Therapy; 2015;15(5):633-40. doi: 10.1517/14712598.2015.1025046. Epub 2015 Apr 3.	3.653	28/124 (Medicine, Research & Experimental)
08	Zecca C , Riccitelli GC, Calabrese P, Pravatà E, Candrian U, Guttmann CRG, Gobbi C. Treatment satisfaction, adherence and behavioural assessment in patients de-escalating from natalizumab to interferon beta. BMC Neurology 2014; 14: 38-45. doi: 10.1186/1471-2377-14-38	2.564	77/193 (Clinical Neurology)
07	Zecca C , Digesu A, Robshaw P, Puccini F, Kullar V, Tubaro A, Gobbi C. Motor and sensory responses after percutaneous tibial nerve stimulation (PTNS) in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice. Eur J Neurol 2014; 21(3):506-511. doi: 10.1111/ene.12339. Epub 2014 Jan 3	4.162	32/193 (Clinical Neurology)
06	Zecca C , Digesu GA, Robshaw P, Singh A, El Neil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis. J Urol 2014;191(3):697-702. doi: 10.1016/j.juro.2013.09.036; Epub	3.696	10/73 Urology & Nephrology)
05	Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C . Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol 2013; 13:101. doi: 10.1186/1471-2377-13-101.	2.564	77/193 (Clinical Neurology)
04	Zecca C , Cereda C, Wetzel S, Tschuor S, Staedler C, Santini F, Nadarajah N, Bassetti CL, Gobbi C. Diffusion-weighted imaging in acute demyelinating myelopathy. Neuroradiol 2012; 54(6): 573-8. doi: 10.1007/s00234-011-0907-6	2.700	72/193 (Clinical Neurology) 5/14 (Neuroimaging) 34/120 (Radiology, Nuclear Medicine & Medical Imaging)
03	Zecca C , Yawalkar N, Gobbi C. Improvement of interferon-beta related skin reactions after halving: first experience of five patients. Pat Pref Adher 2012; 6: 565-567. doi: 10.2147/PPA.S33727	1.333	69/155 (Medicine, General & Internal)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
02	Gobbi C, Digesu' GA, Khullar V, El Neil S, Caccia G, Zecca C . Percutaneous posterior tibial nerve stimulation (PTNS): an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis - preliminary data from a multicentre, prospective, open label trial. Mult Scler 2011; 17(12): 1514-9. doi: 10.1177/1352458511414040	4.472	26/193 (Clinical Neurology)
01	Zecca C , Petrini L, Limoni C, Staedler C, Gobbi C. Tolerability and acceptance of prolonged, low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis. Eur Neurol, 2011; 65: 40-45. doi: 10.1159/000323013. Epub 2010 Dec 22.	1.500	130/193 (Clinical Neurology)

¹ Impact factor, ²Subject specific ranking

Original works in Peer Reviewed-Journals as co-author

No.	Authors / Title / Journal / Volume / Pages / Year	IF ¹	Ranking ²
11	Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C , Gobbi C, Kappos L, Derfuss T Association of Rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis patients With Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2019 Jan 7. doi: 10.1001/jamaneurol.2018.4239. [Epub ahead of print/pubmed/30615019	11.5	5/197 (Clinical Neurology)
10	Disanto G, Zecca C , MacLachlan S, Sacco R, Handunnetthi L, Meier UC, Simpson A, McDonald L, Rossi A, Benkert P, Kuhle J, Ramagopalan SV, Gobbi C. Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol. 2018; 83:1162-1173. doi: 10.1002/ana.25247. [Epub ahead of print]	9.89	6/194 (Clinical Neurology) 14/259 (Neurosciences)
09	Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C , Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C*, Kuhle J*, and the Swiss MS Cohort Study (SMSC) Group (*equal contribution). Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870. doi: 10.1002/ana.24954.	9.638	6/193 (Clinical Neurology) 13/256 (Neurosciences)
08	Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C , et al. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE 2016; 11(3): e0152347. doi:10.1371/journal.pone.0152347.		
07	Gobbi C, Zecca C , Linnebank M, Müller S, You X, Meier R, Borter E, Traber M. Swiss Analysis of Multiple Sclerosis (SAME): A Multicenter, Non-interventional, Retrospective Cohort Study of Disease-Modifying Therapies. Eur Neurol, 2013; 70(1): 35-41.	1.5	130/193 (Clinical Neurology)

No.	Authors / Title / Journal / Volume / Pages / Year	IF ¹	Ranking ²
06	Synofzik M, Ronchi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, Birve A, Biskup S, Zecca C , Fernández-Santiago R, Kaugesaar T, Schöls L, Marklund SL, Andersen PM. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Hum Mol Genet. 2012; 21(16):3568-74.	7.692	28/290 (Biochem & Molecular biol) 13/161 (Genetics & Heredity)
05	*Guglieri M, Magri F, D'Angelo MG, Prella A, Morandi L, Rodolico C, Cagliani R, Mora M, Fortunato F, Bordoni A, Del Bo R, Ghezzi S, Pagliarani S, Lucchiari S, Salani S, Zecca C , Lamperti C, Ronchi D, Aguenouz M, Ciscato P, Di Blasi C, Ruggero A, Moroni I, Turconi A, Toscano A, Moggio M, Bresolin N, Comi GP. Clinical, molecular and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Human Mutation, 2008; 29(2): 258-266.	7.033	15/138 (Genetics & Heredity)
04	*Gabellini D, D'Antona G, Moggio M, Prella A, Zecca C , Adami R, Angeletti B, Ciscato P, Pellegrino MA, Bottinelli R, Green MR & Tupler R. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature, 2006; 439(7079): 973-977.	26.681	2/50 (Multidisciplinary Sciences)
03	*Chiveri L, Sciacco M, Fagiolari G, Serafini M, Ciscato P, Zecca C , Messina S, Comi GP, Bresolin N, Moggio M, Prella A. An adult case of mitochondrial DNA depletion with associated IBM features. Basic and Applied Myology, 2006; 16(1): 5-8.		
02	*D'Adda E, Sciacco M, Fruguglietti ME, Crugnola V, Lucchini V, Martinelli-Boneschi F, Zecca C , Lamperti C, Comi GP, Bresolin N, Moggio M, Prella A. Follow-up of a large population of asymptomatic/ oligosymptomatic hyperckemic subjects. Journal of Neurology, 2006; 253(11): 1399-14403.	2.984	32/147 (Clinical Neurology)
01	*Prella A, Sciacco M, Tancredi L, Fagiolari G, Comi GP, Ciscato P, Serafini M Fortunato F; Zecca C , Gallanti A, Chiveri L, Bresolin N, Scarlato G, Moggio M. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathologica, 2003; 105: 537-542.	2.556	32/135 (Clinical Neurology) 80/198(Neurosciences)(2013)

¹ Impact factor, ²Subject specific ranking

Case Reports, Reviews, Editorials, Letters to the Editor in Peer Reviewed-Journals

Nr.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
13	Chiaro G, Ratila C, Martig F, Zecca C , Gobbi C. Relapsing paralytic ileus in multiple sclerosis requiring surgery: a video case report. Clinical Autonomic Research. 10 Nov 2018 doi.org/10.1007/s10286-018-0573-4	1.635	157/197 (Clinical Neurology) 220/261 (Neurosciences)

Nr.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
12	Zecca C , Antozzi CG, Torri Clerici V, Ferrazzini M, RE, Rossi S, Gobbi C. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation. Acta Neurologica Scandinavica 2017 doi 10.1111/ane.12882.	3.087	68/194 (Clinical Neurology)
11	Bernardini LR, Zecca C , Clerici VT, Gobbi C, Mantegazza R, Rossi S. Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis. Journal of the Neurological Sciences. 2016 Oct 15; 369: 139-140. DOI: 10.1016/j.jns.2016.07.026.	0.36	
10	Zecca C , Panicari L, Disanto G, Maino P, Singh A, Digesu GA, Gobbi C. Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis. Int Urogynecol J. 2016 Apr;27(4):521-7. doi: 10.1007/s00192-015-2814-6.	1.961	33/79 (Obstetrics and Gynecology) 34/76 (Urology & Nephrology)
09	Zecca C , Mainetti C, Blum R, Gobbi C. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection - a case report. BMC Neurology 2015; 15: 249; DOI 10.1186/s12883-015-0504-0.	2.04	113/192 (Clinical Neurology)
08	Caporro M, Disanto G, Gobbi C, Zecca C . Two decades with glatiramer acetate subcutaneous injection - the current role of standard and new high dose – low frequency glatiramer acetate in relapsing remitting multiple sclerosis treatment. Pat Pref Adher 2014; 8: 1123-1134.	1.333	69/155 (Medicine, General & Internal)
07	Zecca C , Caporro M, Györik S, Gobbi C. Life threatening asthma attack during prolonged fingolimod treatment – Case report. Pat Pref Adher 2014;8:987-989.	1.333	69/155 (Medicine, General & Internal)
06	Zecca C , Caporro M, Adami M, Mainetti C, Gobbi C. Fumaric acid esters in psoriasis and multiple sclerosis. Clinical and Experimental Dermatology 2014;39(4):488-491. doi: 10.1111/ced.12326. Epub 2014 Apr 30.	1.329	35/59 (Dermatology)
05	Cereda C, Zecca C , Mazzucchelli L, Valci L, Staedler C, Bassetti C, Gobbi C. Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Mult Scler, 2013; 19(6): 820-3.	4.472	26/193 (Clinical Neurology)
04	Zecca C , Manconi M, Fulda S, Gobbi C. Restless Legs Syndrome in Multiple Sclerosis. CNS & Neurol Disord Drug Targets 2012; 11(8): 1061-9.	3.769	78/252 (Neurosciences)
03	Zecca C , Gobbi C. Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: a critical review. CNS & Neurol Disord Drug Targets 2011; 10(6): 757-61.	3.769	78/252 (Neurosciences)
02	Zecca C , Städler C, Gobbi C. Hydrocephalus during natalizumab treatment. Neurol Sci 2010; 31(5): 635-637.	1.315	143/192 (Clinical Neurology)
01	Zecca C , Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurol 2009; 73: 1418-9.	8.017	4/185 (Clinical Neurology)

¹ Impact factor, ²Subject specific ranking

Other publications

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
86	Patient-Reported and Clinical Outcomes in Teriflunomide-Treated Patients with Relapsing Remitting Multiple Sclerosis: Findings from the Real-World TACO Study. American Academy of Neurology, 71 st Annual Meeting, May 4 to May 10, 2019 Philadelphia, MA. Abstract no		
85	Achtnichts L, Zecca C , Findling O, Kamm C, Müller S, Kuhle J, Salmen A, Lutterotti A, Gobbi C, Mähler R, Stellmes P, Viviani C, Nedeltchev K. A Swiss prospective, multi-centre, observational study to assess the correlation of EDSS with quality of life in MS patients treated with natalizumab. Biogen Research Day 2018, 9 October 2018, Berlin		
84	Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C , Rovira A, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Biseco A, Gass A, Eisele P, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Comi G, Filippi M. Cranio-caudal patterns of cervical cord atrophy progression in MS according to disease phenotype and clinical worsening: a multicenter study. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10-12-October 2018, Berlin. Oral presentation 268. Multiple Sclerosis Journal 2018;24;(S2) 102-103.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
83	Yaldizli Ö, Barro C, Michalak Z, Vehoff J, Lascano AM, Disanto G, Salmen A, Derfuss T, Granziera C, Achtnichts L, Findling O, Nedeltchev K, Kamm CP, Pot C, Schlupe M, Du Pasquier R, von Wyl V, Wuerfel J, Vallejo V, Chan A, Zecca C , Gobbi C, Lalive PH, Müller S, Kappos L, Benkert P, Kuhle J, for the Swiss MS Cohort Study. Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10-12-October 2018, Berlin. Oral presentation 262. Multiple Sclerosis Journal 2018;24;(S2) 97-98.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
82	Brambilla L, Perugini J, Zecca C , Antozzi C, Torri Clerici V, Schilke ED, Confalonieri P, Ferri A, Studer V. Cardiac side effects and related cytokine profile in multiple sclerosis patients treated with alemtuzumab. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10-12-October 2018, Berlin. P938. Multiple Sclerosis Journal 2018;24;(S2) 510.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
81	Pravatà E, Valsasina P, Gobbi C, Zecca C , Filippi M, Rocca MA Influence of T2-hyperintense lesions on cervical spinal cord atrophy and disability in patients with multiple sclerosis 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 10-12-October 2018, Berlin. P797. Multiple Sclerosis Journal 2018;24;(S2) 416.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
80	Gobbi C, Achtnichts L, Derfuss T, Stellmes P, Kamm C, Agosti R, Czaplinski A, Salmen A, Zecca C , Roesch N. Patient-Reported and Clinical Outcomes in Teri unomide-Treated Patients with Relapsing Remitting Multiple Sclerosis: Results from the Real-World TACO Study. Swiss Neurological Society Annual Meeting, 27-28 September 2018, Montreux.		
79	Zecca C , Roth S, Findling O, Perriard G, Messner S, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A. Effectiveness of fingolimod as first-line and second-line treatment for RRMS patients in Switzerland. Swiss Neurological Society Annual Meeting, 27-28 September 2018, Montreux.		
78	Zecca C , Pavelek Z, Prikrylova K, Ghielmetti M, Beeler A, Gobbi C, Tolerability and Quality of Life Outcomes in Patients with Multiple Sclerosis Treated with Interferon- β Autoinjector Swiss Neurological Society Annual Meeting, 27-28 September 2018, Montreux. Submitted		
77	Zecca C , Pravatà E, Riccitelli GC, Gobbi C. Pain network and neuropsychological profile in multiple sclerosis and migraine patients. American Academy of Neurology, 70th Annual Meeting, 21- 27 April 2018, Los Angeles, CA. Neurology 2018; 90(15 Supplement): P2.417.		
76	Brambilla L, Zecca C , Perugini J, Pareja L, Barbic F, Camera G, Riva S, Antozzi A, Gobbi C, Brenna G, Furlan R, Mantegazza R, Rossi S. Alemtuzumab Induces Unexplored Cardiac Effects in Multiple Sclerosis Patients. ACTRIMS Forum 2018, San Diego, California, February 1-3, 2018, P069. Multiple Sclerosis Journal 2018;24: (S1) 42-43.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
75	Disanto G, MacLachlan S, Zecca C , Handunnetthi L, Sacco R, Meier U, Benkert P, Simpson A, McDonald L, Rossi A, Kuhle J, Ramagopalan SV, Gobbi C. Prodromal symptoms of multiple sclerosis in primary care: a case-control study using the UK Clinical Practice Research Datalink (CPRD). 7 th Joint ECTRIMS-ACTRIMS, Paris, 25 - 28 October 2017, P882. Multiple Sclerosis Journal 2017;23: (S3) 456-457.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
74	Malucchi S, Zecca C , Novi G, Signori A, Capobianco M, Laroni A, Realmuto S, Hakiki B, Repice A, Frau J, Signoriello E, Lanzillo R, Gallo F, Di Santo G, Malentacchi M, Scotti B, Uccelli APasta L, Mancardi G, A.Bertolotto A, Sormani MP, Gobbi C, iMUST Study Group. Rituximab real life efficacy in MS: an observational multicentre study. 7 th Joint ECTRIMS-ECTRIMS, Paris, 25 - 28 October 2017, P670. Multiple Sclerosis Journal 2017;23: (S3) 320-321.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
73	Zecca C , Bellavia G, Brambilla L, Pareja Gutierrez L, Gerardi C, Fiori AM, Bernardini L, Camera G, Disanto G, Perugini J, Antozzi C, Confalonieri P, Torri Clerici V, Gobbi C, Mantegazza R, Rossi S. Unexpected systemic reactions following glatiramer acetate 40 mg injections. Experience at 2 Multiple Sclerosis Centers. 7 th Joint ECTRIMS-ECTRIMS, Paris, 25 - 28 October 2017, ePoster EP1461. Multiple Sclerosis Journal 2017;23: (S3) 862-863.	4.840	27/194 (Clinical Neurology) 46/259 (Neurosciences)
72	Zecca C , Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Lalive AH, Czaplinski A. Real-Life Long-Term Effectiveness of Fingolimod in a Swiss Relapsing-Remitting Multiple Sclerosis Cohort. American Academy of Neurology, 69th Annual Meeting, April 22 to April 28, 2017 in Boston, MA. P6.356. Neurology April 18, 2017; 88(16 Supplement): P6.356; 1526-632X.	8.320	
71	Rocca MA, Aboulwafa M, Valsasina P, Preziosa P, Barkhof F, Vrenken H, Gobbi C, Zecca C , Rovira A, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Gass A, Eisele P, Lukas C, Bellenberg B, Comi G, Filippi M. Longitudinal Assessment of Cervical Cord Atrophy Across MS Clinical Phenotypes: A Multicenter Study. American Academy of Neurology, 69th Annual Meeting, April 22 to April 28, 2017 in Boston, MA. Abstract no. 772, platform presentation S2 on 23 April 2017. Neurology April 18, 2017; 88(16 Supplement): S2.002.	8.320	
70	Zecca C , Disanto C, Merlini A, Panicari L, Rodegher M, Romeo M, Messina MJ, Mioila L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Martinelli V, Gobbi C Efficacy and safety of fingolimod 0.5 mg every-other day in multiple sclerosis patients who presented severe adverse events when on conventional fingolimod treatment. 3 rd Congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), 28-30 September 2016, Congress Center Basel, Switzerland, P23. Swiss Med Wkly 2016; 146(S219): 83S.	1.654	

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
69	Zecca C , Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A. Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort. 3 rd Congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), 28-30 September 2016, Congress Center Basel, Switzerland, P20. Swiss Med Wkly 2016; 146(S219): 80S.		
68	Zecca C , Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A. Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK, P1219. Mult Scler J 2016; 22(S3): 640.	1.654	
67	Disanto G, Barro C, Giardiello A, C. Gobbi C, Zecca C , Kuhle J. Serum neurofilament light chain levels in MS: a promising biomarker of clinical and subclinical disease severity. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK, P1602. Multiple Sclerosis Journal 2016; 22(S3): 845.	4.671	27/193 (Clinical Neurology)
66	Barro C, Derfuss T, Nägelin Y, Benkert P, Schädelin S, Yaldizli Ö, Achtnichts L, Nedeltchev K, Kamm CP, Salmen A, Lalive PH, Schlupe M, Du Pasquier R, Müller S, Vehoff J, N. Norgren N, Zecca C , Disanto G, Gobbi C, Kappos L, Kuhle J, for the Swiss MS Cohort Study (SMSC) High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK, P1600 Multiple Sclerosis Journal 2016; 22(S3):843-844.	4.671	27/193 (Clinical Neurology)
65	Perugini J, Torri Clerici V, Zecca C , Pareja L, Camera G, Brambilla L, Bonanno S, Andreetta F, Antozzi C, Torelli F, Gobbi C, Mantegazza R, Rossi S. IL-10 in multiple sclerosis: unexpected excitotoxic effects and clinical implications. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK, P929. Multiple Sclerosis Journal 2016; 22(S3): 470-471.	4.671	27/193 (Clinical Neurology)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
64	Brambilla L, Zecca C , VTorri Clerici V, Pareja L, Camera G, Perugini J, Frangiamore R, Andreetta F, Confalonieri P, Brenna G, Torelli F, Gobbi C, Mantegazza R, Rossi S. CSF contents of IL-17 predicts disability progression and neurodegeneration in relapsing remitting Multiple Sclerosis. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK, P928. Multiple Sclerosis Journal 2016; 22(S3): 469-470.	4.671	27/193 (Clinical Neurology)
63	Zecca C , Merlini A, Disanto G, Panicari L, Rodegher M, Romeo M, Messina MJ, Moiola L, Stefanin C, Ghezi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V. Efficacy and safety of fingolimod 0.5 mg every-other-day in multiple sclerosis patients who presented severe adverse events during conventional fingolimod treatment. 32 nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 14-17 September 2016, London, UK. P1252. Multiple Sclerosis Journal 2016; 22(S3): 661.	4.671	27/193 (Clinical Neurology)
62	Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C , Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm C, Mattle H, Lotter C, Du Pasquier R, Schlupe M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J. The Swiss Multiple Sclerosis Cohort Study (SMSC): a prospective nationwide investigation of disease evolution and the effects of new disease modifying drugs. ECTRIMS, Barcelona, 7-10 October 2015, P775. Mult Scler 2015;21(11 suppl):385-386.doi: 10.1177/1352458515602642.	4.822	22/192 (Clinical Neurology)
61	Zecca C , Disanto G, Muehl S, Gobbi C. Comparison of subjective and objective adherence in patients with multiple sclerosis using RebiSmart(TM). Poster. Annual Meeting of the Swiss Society of Neurology together with Swiss Society for Behavioral Neurology, Swiss Society for Neurorehabilitation, Swiss Society for Headache, Swiss Society for Multiple Sclerosis, Bern, 29./30.10.2015.		
60	Zecca C , Gobbi C, Blum R, Mainetti C. Recurrent Nicolau syndrome following subcutaneous glatiramer acetate injection. Schweizerische Gesellschaft für Dermatologie und Venerologie (SGDV), 97. Jahresversammlung, Zürich, August 26-28 2015: P60.		
59	Gobbi C, Pravata E, Riccitelli G, Sestieri C, Caulo M, Cianfoni A, Zecca C . Precipitation of Cognitive Fatigue Modulates Brain Resting-State Functional Connectivity after Effort in Multiple Sclerosis Patients American Academy of Neurology 67th Annual Meeting, April 18 to April 25, 2015, Washington, A1132 Neurology 2015; 84: 14 (Supplement): P6.151; 1526-632X	8.286	8/192 (Clinical Neurology)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
58	Zecca C , Riccitelli G, Pravata E, Cianfoni A, Staedler C, Cereda C, Disanto G, Panicari L, Gobbi C. The Role of Asymptomatic Spinal Lesions in Predicting Future Attacks in Multiple Sclerosis Patients in a Real World Clinical Setting American Academy of Neurology 67th Annual Meeting, April 18 to April 25, 2015, Washington, A1120 Neurology 2015; 84: 14 (Supplement): P6.120; 1526-632X	8.286	8/192 (Clinical Neurology)
57	Zecca C , Mainetti C, Gobbi C. Relapsing Nicolau syndrome following subcutaneous glatiramer acetate injection Quinta Giornata della Ricerca Clinica della Svizzera Italiana, 27 febbraio 2015, abstract 72.		
56	Zecca C , Riccitelli G, Pravata E, Cianfoni A, Staedler C, Disanto G, Panicari L, Gobbi C. The role of asymptomatic spinal lesions in predicting future attacks in multiple sclerosis patients in clinical setting Quinta Giornata della Ricerca Clinica della Svizzera Italiana, 27 febbraio 2015, abstract 73		
55	Zecca C , Digesu A, Panicari L, Puccini F, Caporro M, Candrian U, Gobbi C. The Severity of urinary symptoms in patients with multiple sclerosis. A multi-centre prospective association study. Quinta Giornata della Ricerca Clinica della Svizzera Italiana, 27 febbraio 2015, abstract 71.		
54	Pravata E, Sestieri C, Caulo M, Riccitelli G, Zecca C , Cianfoni A, Gobbi C. Brain intrinsic Resting-State Functional Connectivity modulation induced by mental effort in Multiple Sclerosis patients with Fatigue. Abstract SSG12-08. Radiological Society of North America, 100th Scientific Assembly and Annual Meeting, Chicago, 30.11–5.12.2014.		
53	Zecca C , Disanto G, Panicari L, Candrian U, Staedler C, Gobbi C. Switching from first line immune modulating treatments to glatiramer acetate: A valid treatment option? Swiss Society of Neurology, Annual Meeting, Interlaken, 29.-31. October 2014		
52	Zecca C , Pravata E, Rocca MA, Riccitelli GC, Cianfoni A, Filippi M, Gobbi C. Brain intrinsic resting-state functional connectivity modulation induced by mental effort in multiple sclerosis patients with fatigue. ECTRIMS, Boston, 10-13 Sept 2014. P117. Multiple Sclerosis 2014;20(1 suppl): 120.	4.863	23/194 (Clinical Neurology)
51	Caporro M, Gobbi C, Zecca C . Life threatening asthmatic crisis after prolonged fingolimod treatment. ECTRIMS, Boston, 10-13 Sept 2014. P874. Multiple Sclerosis 2014; 20(1 suppl): 450.	4.863	23/194 (Clinical Neurology)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
50	Gobbi C, Riccitelli GC, Calabrese P, Pravatà E, Candrian U, Guttman CRG, Zecca C . Treatment Satisfaction, Adherence and Behavioural Assessment in Patients De – escalating from Natalizumab To Interferon Beta. American Academy of Neurology, Philadelphia, 26 Apr -3 May 2014. Neurology 2014; 82 (10 Supplement): P7.235.	8.303	8/194 (Clinical Neurology)
49	Caporro M, Gobbi C, Zecca C . Life threatening asthmatic crisis after 6 months of fingolimod treatment. American Academy of Neurology, Philadelphia, , 26 Apr -3 May 2014. Neurology 2014; 82 (10 Supplement): P2.225.	8.303	1/194 (Clinical Neurology)
48	Zecca C , Kamm CP, Riccitelli GC, Heldner MR, Caporro M, Staedler S, Gobbi C. Natalizumab in Multiple Sclerosis with Spinal Involvement. American Academy of Neurology, Philadelphia, , 26 Apr -3 May 2014. Neurology 2014; 82 (10 Supplement): P7.209.	8.303	1/194 (Clinical Neurology)
47	Zecca C , Kamm CP, Riccitelli G, Heldner MR, Caporro, M, Städler C, Gobbi C. Natalizumab in spinal relapsing-remitting multiple sclerosis. European Neurology Society 2014; Abstract PP1229. Joint Congress of European Neurology, May 31 to June 3 2014, Istanbul, Turkey. European Journal of Neurology 21 (Suppl. 1): 457. J Neurol 2014;261(S1):S303	3.852	36/194 (Clinical Neurology)
46	Zecca C , Riccitelli GC, Caporro M, Kamm C, Heldmer MR, Pravatà E, Panicari L, Candrian U, Gobbi C. Natalizumab in spinal relapsing-remitting multiple sclerosis. Quarta Giornata della Ricerca Clinica della Svizzera Italiana, 28 marzo 2014; Abstract 3		
45	Pravatà E, Sestieri C, Caulo M, Riccitelli G, Zecca C , Pifferini V, Navarajah N, Cianfoni A, Gobbi C. Modulation of brain MRI functional connectivity induced by cognitive effort in MS patients with fatigue. Quarta Giornata della Ricerca Clinica della Svizzera Italiana, 28 marzo 2014, Abstract 1		
44	Bontadelli J, Staedler C, Zecca C , Gobbi C. Repeated rituximab infusions in the treatment of progressive multiple sclerosis. Swiss Federation of Clinical Neuro-societies, Montreux, June 5-7, 2013; P87. Schweizer Archiv für Neurologie und Psychiatrie 2013; 164 (Suppl. 6): 28S.		

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
43	Zecca C , Adami M, Mainetti C, Gobbi C. Psoriasis and multiple sclerosis: Fumaric acid esters kill two birds with a stone. Swiss Federation of Clinical Neuro-societies, Montreux, June 5-7, 2013; P84. Schweizer Archiv für Neurologie und Psychiatrie 2013; 164 (Suppl. 6): 27S.		
42	Zecca C , Caporro M, Kamm C, Heldner MR, Riccitelli G, Pravata E, Staedler C, Gobbi C. Efficacy of natalizumab in spinal relapsing-remitting multiple sclerosis. 44 Congresso della Società italiana di Neurologia, Milano, 5 November 2013; P700		
41	Zecca C , Candrian U, Adami M, Meier DS, Cotton F, Sintzel M, Leppert D, Guttman RG, Nadarajah N, Tschuor S, Gobbi C. Natalizumab de-escalation to interferon beta 1b in multiple sclerosis: a randomized, controlled, pilot trial. Terza giornata della ricerca clinica della Svizzera Italiana, 22 marzo 2013. Libro degli Abstracts S. 70.		
40	Bontadelli J, Staedler C, Zecca C , Gobbi C. Repeated rituximab infusions in the treatment of progressive multiple sclerosis. Terza giornata della ricerca clinica della Svizzera Italiana, 22 marzo 2013. Libro degli Abstracts S. 30.		
39	Zecca C , Yawalkar N, Städler C, Gobbi C. Diluent halving: a new strategy to optimize interferon beta-1b-related skin reactions? European Neurology Society, Prague, June 9-12, 2012. P473. J Neurol 2012; 259(S1): S111.	3.578	37/193 (Clinical Neurology)
38	Zecca C , Yawalkar N, Gobbi C. Improvement of interferon-beta related skin reactions after halving: first experience of five patients. Clinical Neurophysiology 2012; 123: e114. (Abstract)	3.144	55/193 (Clinical Neurology)
37	Zecca C , Meier S, Tschuor S, Nadarajah N, Cotton F, Sinzel M, Leppert D, Guttman CRG, Gobbi C. Natalizumab de-escalation to interferon-beta-1b in multiple sclerosis: a randomised, controlled, pilot trial 28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple- Sclerosis, OCT 10-13, 2012, Lyon, France Multiple Sclerosis Journal 2012; 18(S4): 463-464	4.472	26/193 (Clinical Neurology)
36	Digesu A, Puccini F, Hendricken C, Bhide AA, Khullar V, Tubaro A, Caccia G, Testorio SBellinato MC, Zecca C , Gobbi C. Motor and/or sensory response during percutaneous tibial nerve Stimulation (ptns)-do they predict treatment outcome? 37th Annual IUGA Meeting, Brisbane, Australia, 4--8 September 2012 International Urogynecology Journal Meeting Abstract 39; 23(S2): S84.	2.169	22/78 (Obstetrics & Gynecology) 26/73 (Urology & Nephrology)

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
35	Gobbi C, Zecca C , Meier S, Cotton F, Sintzel M, Leppert D, Guttmann CRG. Natalizumab de-escalation to interferon beta 1b in multiple sclerosis: a randomized, controlled pilot trial. 85. Kongress der Deutschen Gesellschaft für Neurologie, 26. – 29. September 2012, Hamburg Deutsche Gesellschaft für Neurologie Kongress 2012 P659.		
34	Economou NT, Manconi M, Bonanni E, Marelli S, Gobbi C, Petrini-Klieber L, Maestri M, Iacopini E, Zecca C , Gola-Bricalli M, Cereda C, Limoni C, Petrini O, Murri L, Ferini-Strambi L, Bassetti C. Fatigue in sleep disorders before and after treatment, and in other neurological diseases - Assessment of its severity and its nature. P 481. Journal of sleep research 2012; 21(SI):160	3.043	56/193 (Clinical Neurology)
33	Gobbi C, Zecca C , Linnebank M, Müller S, Meier R, Borter E, Traber M. Final results of the SAME (Swiss Analysis of Multiple Sclerosis) study comparing four disease-modifying treatments for multiple sclerosis. ECTRIMS Amsterdam, October 19-22, 2011 P937. Multiple Sclerosis 2011; 17(10 suppl): S422.	4.472	26/193 (Clinical Neurology)
32	Zecca C , Meier S, Candrian U, Cotton F, Sintzel M, Guttmann C.R.G, Gobbi C. De-escalation after natalizumab treatment with interferon-beta-1b in patients with relapsing remitting multiple sclerosis: 6-month interim results of a pilot study. ECTRIMS Amsterdam, October 19-22, 2011 P461 Multiple Sclerosis 2011; 17(10 suppl): S193-S194.	4.472	26/193 (Clinical Neurology)
31	Zecca C , Cereda C, Wetzel S, Tschuor S, Staedler C, Nadarajah N, Bassetti C, Gobbi C. Diffusion-weighted imaging in acute demyelinating myelopathy. European Neurology Society, Lisbon, May 28-31, 2011. P791 J Neurol 2011; 258(S1): S222.	3.578	37/193 (Clinical Neurology)
30	Zecca C , Digesu C, Gobbi C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis. ECTRIMS, Göteborg, October 13-16, 2010, P517. Multiple Sclerosis 2010; 16(10 suppl): S175.	4.255	27/192 (Clinical Neurology)
29	Zecca C , Gobbi C, Economou N, Gola-Bricalli, M, Penner IK, Bassetti CL, Calabrese P. Fatigue in multiple sclerosis and sleep disorders — similarities and differences. ECTRIMS, Göteborg, October 13-16, 2010, P803 Multiple Sclerosis 2010; 16(10 suppl): S279.	4.255	27/192 (Clinical Neurology)
28	Zecca C , Limoni C, Bassetti CL, Gobbi C. Safety and efficacy of prolonged mitoxantrone therapy. Swiss Federation of Clinical Neuro-societies; Basel, June 2-4, 2010. Schweizer Archiv für Neurologie und Psychiatrie 2010; 161(S1): S7.		

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
27	Zecca C , Naegelin Y, Sturzenegger R, Pohlman U, Gensicke H, D'Souza M, Hafner P, Weier K, Chang V, Gobbi C, Kappos L. Natalizumab for relapsing-remitting multiple sclerosis – experience in two Swiss centres. ECTRIMS Düsseldorf, September 9-12, 2009, P771 Multiple Sclerosis 2009; 15(S2): S233.	4.230	29/185 (Clinical Neurology)
26	Ronchi D, Raimondi M, Zecca C , Bordoni A, Corti S, Gobbi C, Comi GP. Novel homozygous mutation in SOD1 gene in a patient with familial amyotrophic lateral sclerosis. 19 th Meeting of the European Neurological Society, Milan, June 20-24, 2009. P220 J Neurol 2009; 256(S2): 79-80.	3.853	33/185 (Clinical Neurology)
25	*Guglieri M, Magri F, D'Angelo MG, Parini B, Prella A, Cagliani R, Parini B, Fortunato , Bordoni , Del Bo, Ghezzi S, Lucchiari S, Salani S, Zecca C, Lamperti , Ronchi, D, Ciscato P, Morandi L, Mora M, Moroni I, Rodolico C, Toscano A, Moggio M, Bresolin N, Comi GP. Clinical, molecular and protein correlations in a large sample of genetically diagnosed italian limb girdle muscular dystrophy patients. 59th Annual Meeting of the American-Academy-of-Neurology, APR 28-MAY 05, 2007, Boston. Neurology 2007; 68(12 S1):A3.		
24	* Zecca C , Crugnola V, Angeletti B, Ciscato P, Lamperti C, Tiberio F, Prella A, Bresolin N, Tupler R, Moggio M. Facio-Scapulo-Humeral dystrophy (FSHD): morphological characterization of mouse model. XIth International Congress on Neuromuscular Diseases, Istanbul, July 2-7, 2006. Neuromuscul Disord. 16 (Suppl 1):S71, 2006.	2.615	44/147 (Clinical Neurology) 94/200 (Neurosciences)
23	*Guglieri M, Magri F, Cagliani R, D'Angelo MG, Prella A, Fortunato F, Lucchiari S, Salani S, Del Bo R, Ghezzi S, Zecca C , Lamperti C, Morandi L, Mora M, Moggio M, Bresolin N, Comi GP. Limb-Girdle muscular dystrophies: clinical features and genetic frequency in a large Italian population. VI Congress of Italian Association for Miology, Rome, May 24-27, 2006. Basic and Applied Myology 2006; 16(1):49.		
22	*Tupler R, Gabellini G, Moggio M, Prella A, Angeletti B, Zecca C , Bottinelli R, D'Antona G, Green M. A mouse model of facioscapulohumeral muscular dystrophy. Congrès International de Miologie, Symposium "Facioscapulohumeral muscular dystrophy", Nantes, France, May 9-13, 2005. Myologie 2005 :		

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
21	* Naini A, Lucchini V, Zecca C , Ciscato P, Serafini M, Prella A, Bresolin N, Moggio M. Statin related myopathy and COQ 10 deficiency. Congrès International de Miologie, communication n° 368, Nantes, France, May 9-13, 2005. Myologie 2005 : 177.		
20	*Guglieri M, Magri F, Cagliani R, D'Angelo M.G, Prella A, Fortunato F, Lucchiari S, Salani S, Del Bo R, Bordoni A, Ghezzi S, Zecca C , Lamperti C, Moggio M, Bresolin N, Comi GP. Autosomal dominant and recessive limb-girdle muscular dystrophies: relative frequency in a large Italian population. 15th ENS Meeting, Vienna, 18-22 June 2005, P593. Journal of Neurology 2005; 252 (Suppl 2): II/153.	2.844	29/148 (Clinical Neurology)
19	*Lamperti C, Fruguglietti M.E, D'Adda E, Marchesi C, Zecca C , Lucchini V, Sciacco M, Tiberio F, Moggio M, Prella A. Idiopathic orbital Myositis responsive to IG EV. 36th SIN Meeting, Cernobbio, 8-12 October 2005. Neurological Sciences 2005; 26 (Suppl): S237.	0.779	120/148 (Clinical Neurology) 173/200 (Neurosciences)
18	* Zecca C , Ciscato P, Fagiolari G, Angeletti B, Gabellini D, Prella A, Bresolin N, Moggio M, Tupler R. FSHD mouse model: morphological characterization. 36th SIN Meeting, Cernobbio, 8-12 October 2005. Neurological Sciences 2005; 26 (Suppl): S10.	0.779	120/148 (Clinical Neurology) 173/200 (Neurosciences)
17	* Zecca C , Ciscato P, Fagiolari G, Angeletti B, Gabellini D, Prella A, Bresolin N, Moggio M, Tupler R. Morphological features of FSHD mouse model. 5th Congress of Italian Association for Miology, Naples, June 16-18, 2005. Basic and Applied Myology 2005; 15(2): 119.		
16	*Lamperti C, Naini A, Lucchini V, Zecca C , Prella A, Fagiolari G, Bresolin N, Di Mauro S, Moggio M. Statin related myopathy and COQ 10 deficiency. 5th Congress of Italian Association for Miology, Naples, June 16-18, 2005. Basic and Applied Myology 2005; 15(2): 107.		
15	*Lamperti C, D'Adda E, Marchesi C, Fruguglietti ME, Zecca C , Lucchini V, Sciacco M, Moggio M, Prella A. Idiopathic orbital myositis responsive to Ig EV. 5th Congress of Italian Association for Miology, Naples, June 16-18, 2005. Basic and Applied Myolog, 2005; 15(2): 106.		
14	*Sciacco M, Prella A, Fagiolari G, Ciscato P, Serafini M, Livraghi S, Napoli L, Lamperti C, Zecca C , Fruguglietti ME, Lucchini V, Crugnola V, Ripolone M, Comi GP, Bordoni A, Fortunato F, Torrente I, Galbiati S, Locatelli F, Corti S, Del Bo R, Lucchiari S, Salani S, Guglieri M, Virgilio R, Grimoldi N, Tiberio F, Silvani E, Bresolin N, Moggio M. Bank of DNA, cell lines and nerve-muscle-cardiac tissues. Telethon Scientific Convention, Salsomaggiore Terme 6-8 March 2005.		

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
13	*Casellato C, Terenghi F, Scarlato M, Cappellar A, Zecca C , Nobile-Orazio E. POEMS syndrome without overt osteosclerotic myeloma improving with melphalan monoteraphy. 14 th Meeting of the European Neurological Society, Barcelona, June 26-30, 2004. Journal of Neurology 2004; 251(Suppl.3): III166.	3.140	21/140 (Clinical Neurology)
12	*Sciacco M, Fruguglietti E, Lucchini V, Zecca C , Lamperti C, galbiati S, Tiberio F, Comi GP, Bresolin N, Moggio M, Prella A. Idiopatic hyperCKemia: follow up of a large population of asyntomatic/oligosymptomatic patients. 14 th Meeting of the European Neurological Society, Barcelona, June 26-30, 2004. Journal of Neurology 2004; 251(Suppl.3): III83.	3.140	21/140 (Clinical Neurology)
11	*D'Adda E, Sciacco M, Martinelli F, Fruguglietti E, Lucchini V, Zecca C , Lamperti C, Tiberio F, Comi GP, Bresolin N, Moggio M, Prella A. Idiopatic hyperCKemia: follow up of a large population of asyntomatic/oligosymptomatic patients. XXXV Congress of the Italian Neurological Society. Neurological Sciences 2004; 25: S45.	1.059	96/140 (Clinical Neurology) 160/198 (Neurosciences)
10	*Cagliani R, Magri F, Rodolico C, Merlini L, Sironi M, Prella A, Toscano A, Zecca C , Aguenouz M, Fortunato F, Vita G, Bresolin N, Comi GP. Novel dysferlin gene mutation in a clinically heterogeneous group of Italian patients. IV Congress of Italian Association for Miology, Taormina, May 6-8, 2004. Basic and Applied Myology 2004; 14(2): 104.		
09	*D'Adda E, Sciacco M, Tancredi L, Fruguglietti E, Lucchini V, Zecca C , Lamperti C, Tiberio F, Comi GP, Bresolin N, Moggio M, Pelle A. Follow-up in a large population of asympptomatic/oligosymptomatic hyperCKemic patients. IV Congress of Italian Association for Miology,Taormina, May 6-8, 2004. Basic and Applied Myology 2004; 14(2): 103.		
08	*Cagliani R, Sironi M, Prella A, Moggio M, Toscano A, Locatelli F, Rodolico C, Tiberio F, Zecca C , Fortunato F, Grimoldi N, Bresolin N, Comi GP. Molecular analysis of LGMD-2B and MM patients: identification of a novel DYSF mutation and possible founder effect in the Italian population. III Congress of Italian Association for Miology, Padova, June 12-15, 2003. Basic and Applied Myology 2003; 13(5): 227.		

No.	Authors / Title / Journal / Year / Volume / Pages	IF ¹	Ranking ²
07	<p>*Lamperti C, Cappellini A, Fagiolari G, Ciscato C, Pelle A, Grimoldi N, Fruguglietti ME, Zecca C, Bresolin N, Moggio M.</p> <p>Alpha dystroglycan glycosilation defect in a case of congenital muscular dystrophy. Histological and immunocytochemical studies in a skeletal muscle and in autoptic brain tissue.</p> <p>III Congress of Italian Association for Miology, Padova, June 12-15, 2003.</p> <p>Basic and Applied Myology 2003; 13(5): 234.</p>		
06	<p>*Lamperti C, Cagliani R, Ciscato P, Lucchini C, Zecca C, Comi GP, Fagiolari G, Prella A, Bresolin N, Tiberio F, Moggio M.</p> <p>Congenital muscular dystrophy presenting as inflammatory miopathy.</p> <p>III Congress of Italian Association for Miology, Padova, June 12-15, 2003.</p> <p>Basic and Applied Myology 2003; 13(5): 233.</p>		
05	<p>*Sciacco M, Gallanti A, Prella A, Fagiolari G, Ciscato P, Serafini M, Livraghi S, Napoli L, Lamperti C, D'Adda E, Zecca C, Fruguglietti ME, Lucchini V, Comi GP, Bordoni A, Fortunato F, Torrente I, Galbiati S, Locatelli F, Corti S, Del Bo R, Crimi M, Lucchiari S, Salani S, Grimoldi N, Tiberio F, Silvani E, Bresolin N, Moggio M.</p> <p>Bank of DNA, cell lines and nerve-muscle-cardiac tissues.</p> <p>Telethon Scientific Convention, Riva del Garda, 23-25 November 2003.</p>		
04	<p>*Crimi M, Galbiati S, Bordoni A, Strazzer S, Sciacco M, Perini MP, Pintucci M, Zecca C, Biunno I, Moggio M, Bresolin N, Scarlato G, Comi GP.</p> <p>The first maternally-inherited mutation of mitochondrial t-RNA gene results in retinitis pigmentosa and neuro-sensorial hypoacusia.</p> <p>II Congress of Italian Association for Miology, Turin, June 14-15, 2002.</p> <p>Basic and Applied Myology 2002; 12(3): 125.</p>		
03	<p>*Cagliani R, Sironi M, Rodolico C, Toscano A, Lucchiari S, fortunate F, Prella A, Tancredi L, Salani S, Sciacco M, Zecca C, Gallanti A, Moggio M, Comi G, Bresolin N.</p> <p>A novel splice-site mutation in a LGMD-2B family causing activation of a cryptic site and total dysferlin absence.</p> <p>II Congress of Italian Association for Miology, Turin, June 14-15, 2002.</p> <p>Basic and Applied Myology 2002; 12(3): 122.</p>		
02	<p>*Gallanti A, Prella A, Sciacco M, Fagiolari G, Ciscato P, Chiveri L, Lamperti C, D'Adda E, Zecca C, Napoli L, Serafini M, Bresolin N, Comi GP, Torrente I, Galbiati S, Locatelli F, Del Bo R, Salani S, Lucchiari S, Bordoni A, Fortunato F, Grimoldi N, Tiberio F.</p> <p>Bank of DNA and nerve-muscle tissues.</p> <p>Telethon Scientific Convention, Riva del Garda, 24-26 November 2002.</p>		
01	<p>*Moggio M, Gallanti A, Prella A, Sciacco M, Comi GP, Bresolin N, Fagiolari G, Ciscato P, Tancredi L, Chiveri L, Lamperti C, Zecca C, Lombardi F, Bordoni A, Fortunato F, Scarlato G.</p> <p>Bank of DNA and nerve-muscle tissues.</p> <p>Telethon Scientific Convention, Riva del Garda, Nov 18-20 - 2001.</p>		

¹ Impact factor, ²Subject specific ranking

5 Sezioni di libri, reviews, libri

No.	Authors / Title / Journal / Volume / Pages / Year
10	Panicari L, Zecca C , Gobbi C. Sclerosi multipla. Dalla diagnosi precoce alla terapia attuale. Labmed 2016;7/8: 265-262.
09	Gobbi C., Zecca C . Individualisierte Therapiekonzepte bei Multipler Sklerose. Concepts thérapeutiques personnalisés dans la sclérose en plaques. www.neurocase.ch
08	Zecca C , Adami M, Gobbi C. Gylenia® (Fingolimod): il primo trattamento orale per la sclerosi multipla. Tribuna Medica Ticinese 2013; 78: 109-112.
07	Zecca C , Gobbi C. Studi comparativi randomizzati tra le terapie di primo livello della sclerosi multipla. Tribuna Medica Ticinese 2012; 77: 437-442.
06	Zecca C , Gobbi C. Trattamento analgesico dell'emicrania. Tribuna Medica Ticinese 2012; 77: 431-436.
05	Zecca C , Gobbi C. Insufficienza venosa cerebro-spinale cronica (CCSVI) e sclerosi multipla (SM). Tribuna Medica Ticinese 2011; 76: 21-23.
04	Zecca C , Gobbi C. Polineuropatie – approccio sequenziale alla diagnostica. Tribuna Medica Ticinese 2010; 75: 257-260.
03	Zecca C , Gobbi C. Sclerosi multipla: aspetti generali. Tribuna Medica Ticinese 2010; 75: 55.
02	Gobbi C, Zecca C . Wirksamkeit und Vertäglichkeit von Natalizumab. Multiple Sklerose special in Medical Tribune 2010; 5: 12.
01	Zecca C , Gobbi C. Journal Club: Trattamento steroideo nella sclerosi multipla: lo studio NORMIMS. Tribuna Medica Ticinese 2009; 74: 455.

6 Oral presentations

No.	Author / Title / Event
01	Zecca C . Treatment de-escalation in MS 3 rd Congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), 28-30 September 2016, Congress Center Basel, Switzerland, 30.09.2016, 11:30-12:00.